clinicians

Henning Bliddal, MD, MSci Credit: The Parker Institute Semaglutide Shows Promise in Reducing Knee Osteoarthritis Pain in Obese Individuals In a groundbreaking study, semaglutide, a medication primarily known for its …

New Hope for IgA Nephropathy: Promising Treatment Advancements The landscape of IgA nephropathy (IgAN) management is experiencing a remarkable transformation. Driven by decades of research unraveling the disease’s intricate pathophysiology, …

Lean Liver Disease: A Hidden Threat Affecting Millions of Americans New research is shining a light on a concerning trend: lean metabolic dysfunction-associated steatotic liver disease (MASLD) is affecting a …

Semaglutide Shows Promise for Non-Diabetic Chronic Kidney Disease in Landmark SMART Trial Exciting news emerged from Kidney Week 2024 as the landmark SMART trial unveiled promising results for semaglutide (Ozempic/Wegovy) …

Semaglutide Shows Promise in Reducing Cardiovascular and All-Cause Mortality in Patients with Type 2 Diabetes and CKD New data from the FLOW trial, presented at the American Society of Nephrology’s …

Hiddo Heerspink, PharmD, PhDCredit: George Institute for Global Health Semaglutide Shows Promise in Managing Chronic Kidney Disease Without Diabetes A recent clinical trial suggests semaglutide (Ozempic) may hold significant potential …

Will Herrington, MA, MBBS, MD, FRCP, FERA Credit: Oxford University Empagliflozin Continues to Protect Kidney Health After Trial Completion New data from the EMPA-KIDNEY trial presented at ASN Kidney Week …

Jennifer Yi-Chun-Lai Yee, MD, PhD, MPHCredit: Michigan Medicine Sparsentan Shows Promise for Patients with Genetic Focal Segmental Glomerulosclerosis (gFSGS) A recent analysis of the DUPLEX trial, the largest clinical trial …

Intellia Therapeutics’ Nex-Z Shows Promise for Treating ATTR-CM Intellia Therapeutics is making waves in the fight against ATTR amyloidosis with cardiomyopathy (ATTR-CM) with its groundbreaking gene editing therapy, nex-z (formerly …